<DOC>
	<DOCNO>NCT02254824</DOCNO>
	<brief_summary>The purpose EMINENT study evaluate efficacy Xuezhikang atorvastatin hypertensive patient low/moderate cardiovascular risk .</brief_summary>
	<brief_title>Effects Underlying Mechanism Lipid Lowering Intervention Vascular Protection Hypertensive Patients</brief_title>
	<detailed_description>EMINENT study evaluate efficacy Xuezhikang atorvastatin vascular function protection hypertensive patient low/moderate cardiovascular risk .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>All patient must meet hypertension low moderate cardiovascular risk follow 2010 Guidelines prevention treatment hypertension China Secondary Hypertension Women pregnant lactate History mental instability , major psychiatric illness adequately control stable therapy Type 2 Diabetes Active liver disease impair liver function test Impaired renal function Uncontrolled cardiac arrhythmia Patient unable give inform consent Any condition situation , opinion investigator , might pose risk patient confound result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Xuezhikang</keyword>
	<keyword>atorvastatin</keyword>
</DOC>